ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1036

Ocular Involvement and Treatment in Sarcodosis. Study of 41 Patients of a Series of 383 Patients from a Single University Hospital

David Martinez-Lopez1, Jorge Javier Gaitan-Valdizan2, Raul Fernandez-Ramon3, Rosalia Demetrio-Pablo3, Lara Sanchez-Bilbao3, Inigo Gonzalez-Mazon4, José Luis Martín-Varillas5, Miguel Ángel González-Gay6 and Ricardo Blanco3, 1Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, 2Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Hospital Universitario Marques de Valdecilla, Santander, Spain, 4Hospital Universitario Marques de Valdecilla, Bezana, Spain, 5Hospital Sierrallana, Torrelavega, Spain, 6Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

Meeting: ACR Convergence 2020

Keywords:

Session Information

Date: Sunday, November 8, 2020

Session Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Sarcoidosis, Interstitial Lung Disease, & Inflammatory Eye Disease

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Background: The eye is a common and potential severe complication of sarcoidosis. Topical and systemic corticosteroids are the first-line treatment. Conventional and biological immunosuppressants are frequently needed.

Objectives: To assess the frequency, clinical and treatment of ocular involvement of sarcoidosis.

Methods: Study of a large cohort (n=383) of systemic sarcoidosis from a single university hospital. All consecutive patients diagnosed with sarcoidosis from January 1, 1999 to January 1, 2019 according the ATS/ERS/WASOG criteria (Eur Respir J 1999;14:735–737) were included.

Results: 41 (22 women/19 men) of 383 (10.7%) patients had ocular involvement, mean age 44.8±16 years. Uveitis (n=34; 82.9%) was the most common ocular manifestation, especially anterior uveitis (n=18; 52.9%). Ocular surface and eye orbit may also be affected (table 1).

In addition to topical and systemic corticosteroids, conventional (n=23; 56.1%) and biologic (n=14; 34.1%) immunosuppressive drugs were required. Adalimumab and Infliximab were the most used biologic treatments (table 2).

Cystoid macular edema (CME) and Retinal Vasculitis was observed in both cases in 3 (7.3%) patients, 2 of them (66.7%) required biological treatment. Papilitis appeared in 7 (17.1%) cases, biological treatment was needed in 3 (42.9%) patients.

The most frequent sequels were cataract (n=9, 21.9%), intraocular hypertension (n=5; 12.2%) and pupil alterations (n=4; 9.7%). The average of the best corrected visual acuity was 0.6±0.3 at diagnosis and 0.7±0.3 after one year follow up.

Conclusion: Ocular involvement of sarcoidosis is a relative frequent and potential severe complication, especially if panuveitis is presented.

Disclosure: D. Martinez-Lopez, Lilly, 2; J. Gaitan-Valdizan, None; R. Fernandez-Ramon, None; R. Demetrio-Pablo, None; L. Sanchez-Bilbao, None; I. Gonzalez-Mazon, None; J. Martín-Varillas, None; M. González-Gay, None; R. Blanco, None.

To cite this abstract in AMA style:

Martinez-Lopez D, Gaitan-Valdizan J, Fernandez-Ramon R, Demetrio-Pablo R, Sanchez-Bilbao L, Gonzalez-Mazon I, Martín-Varillas J, González-Gay M, Blanco R. Ocular Involvement and Treatment in Sarcodosis. Study of 41 Patients of a Series of 383 Patients from a Single University Hospital [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/ocular-involvement-and-treatment-in-sarcodosis-study-of-41-patients-of-a-series-of-383-patients-from-a-single-university-hospital/. Accessed October 19, 2021.

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ocular-involvement-and-treatment-in-sarcodosis-study-of-41-patients-of-a-series-of-383-patients-from-a-single-university-hospital/